RPRX up +56.90% percent right now. $RPRX High is at 10.25

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
RPRX up +56.90% percent right now. $RPRX High is at 10.25 and the Low 7.66 with current volume of 8,183,000.

Recent News posted below.

RPRX Repros Therapeutics Inc Recent Headline News

Nasdaq stocks posting largest percentage increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SWIR: 33.90 (+0.30), PERI: 5.75 (-0.35), UNXL: 5.31 (+0.77), TREE: 47.03 (+3.12), SSRI: 5.20 (+0.88), STMP: 42.92 (+0.93), RPRX: 10.12 (+3.67), NYNY: 7.74 (-0.22), SHLD: 42.81 (+10.14), AREX: 10.73 (+1.88), PGNX: 5.37 (+0.76), ECYT: 6.03 (-0.46), SSO.TO: 5.90 (+0.95), SGMA: 7.21 (-0.64), SW.TO: 38.39 (-0.04), PLNR: 6.40 (+0.01)

Sears Soars Nearly +40% As REIT News Boosts Confidence
at The Street - Fri Nov 07, 2:42PM CST
Repros Therapeutics Inc (NASDAQ:RPRX), Sears Holdings Corp (NASDAQ:SHLD) and Allied Nevada Gold Corp. (NYSEMKT:ANV) are among the top-gaining billionaire stock picks of the day. On the losing end ar...
ANV: 1.05 (+0.19), AMSC: 1.17 (-0.19), RPRX: 10.12 (+3.67), SHLD: 42.81 (+10.14), STAY: 18.30 (-5.00)

Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
at The Street - Fri Nov 07, 10:07AM CST
Shares of Repros Therapeutics (RPRX) soared in morning trading Friday after the biopharmaceutical company held what it called a "constructive meeting" with the FDA regarding its testosterone-boosting drug Androxal.
RPRX: 10.12 (+3.67)

Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
GlobeNewswire - Thu Nov 06, 3:21PM CST
-- No New Clinical Studies Requested
RPRX: 10.12 (+3.67)

Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 91.06 (-3.49), PBH: 32.79 (-4.53), RPRX: 10.12 (+3.67), HSP: 56.32 (-0.32)

63.7% Return Seen to Date on SmarTrend Repros Therapeutics Call (RPRX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 63.72% as of today's recent price of $6.48.
RPRX: 10.12 (+3.67)

Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.04 (+0.41), PTX: 9.09 (-0.17), AKRX: 36.59 (-1.29), RPRX: 10.12 (+3.67), NKTR: 13.35 (-0.21)

Repros to Webcast Investor and Analyst Day on October 31st
GlobeNewswire - Mon Oct 27, 3:01PM CDT
Repros Therapeutics Inc.(Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held in New York City on Friday, October 31, 2014 beginning at 7:30 a.m. Eastern Time.
RPRX: 10.12 (+3.67)

Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 10:18AM CDT
Will Amgen (AMGN) go the Abbott (ABT) way and split into two separate companies?
PCYC: 133.49 (-3.63), NPSP: 27.49 (+0.15), RPRX: 10.12 (+3.67), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), REGN: 377.84 (+0.90), CELG: 106.45 (-0.69)

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Repros Therapeutics Inc. - RPRX
PR Newswire - Mon Oct 20, 12:33PM CDT
Levi & Korsinsky, LLP is investigating Repros Therapeutics Inc. ("Repros" or the "Company" (NasdaqCM: RPRX) in connection with possible violations of federal securities laws.
RPRX: 10.12 (+3.67)

INVESTOR ALERT: Investigation of Repros Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Mon Oct 20, 9:36AM CDT
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Repros Therapeutics Inc. ("Repros Therapeutics" or the "Company" (NASDAQ: RPRX) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning the Company's business and financial prospects.
RPRX: 10.12 (+3.67)

Repros Therapeutics Down 64.6% Since SmarTrend Downtrend Call (RPRX)
Comtex SmarTrend(R) - Mon Oct 20, 9:08AM CDT
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 64.61% as of today's recent price of $6.32.
RPRX: 10.12 (+3.67)

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc.
PR Newswire - Mon Oct 20, 8:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Repros Therapeutics, Inc. ("Repros Therapeutics" or the "Company" (NasdaqCM: RPRX -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
RPRX: 10.12 (+3.67)

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm
PR Newswire - Fri Oct 17, 7:28PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Repros Therapeutics Inc. ("Repros" or the "Company" (NASDAQ: RPRX).
RPRX: 10.12 (+3.67)

GE and Urban Outfitters are big market movers
AP - Fri Oct 17, 3:31PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
URBN: 31.18 (+0.02), GE: 26.41 (+0.05), CLV: 10.77 (+0.44), RPRX: 10.12 (+3.67), CLF: 11.17 (+0.63), ATHN: 123.82 (-1.94), MS: 35.66 (+0.35)

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Repros Therapeutics Inc. - RPRX
Business Wire - Fri Oct 17, 2:17PM CDT
The Rosen Law Firm announces that it is investigating potential securities claims against Repros Therapeutics Inc. (NASDAQ: RPRX) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
RPRX: 10.12 (+3.67)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Broadridge Brings Boyman In to Sharpen Its Market Story

Updated Category News Views 66

Financial plumbing rarely gets applause, which is precisely why Broadridge needs somebody who can explain its value without turning the pitch into alphabet soup. Lauren Boyman arrives as chief marketing and communications officer on November 23, taking charge of global marketing, corporate communications, product positioning, digital strategy, lead generation and thought...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 45

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 14

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Trucking Hub Bets on Faster MVR Checks Nationwide Today

Updated Category News Views 38

Driver paperwork is where plenty of supposedly modern fleet systems still go to die. Trucking Hub’s Nov. 18 launch of GetMVR.com takes a clean swing at that mess: an online platform for ordering Motor Vehicle Records in all 50 states, with instant reports available in 48. It is not glamorous software, and frankly that is why it may matter. Fleets do not lose sleep over...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 180

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 167

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 31

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 54

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 0

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading

Top 5 Most Recently Viewed Articles

Prinses Máxima Center Enhances Genomics with Callisto™ Innovation

Updated Category News Views 300

Prinses Máxima Center's Partnership with Volta Labs The Prinses Máxima Center for Pediatric Oncology is making headlines with its recent acquisition of the Callisto™ platform from Volta Labs. This major step forward aims to enhance efficiency in sample preparation across a variety of genomics workflows, specifically designed for both Illumina and Oxford Nanopore...

Continue Reading
Keros Therapeutics to Showcase Innovations at Key Conferences

Updated Category News Views 152

Exciting Participation of Keros Therapeutics in Major Conferences Keros Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape by focusing on innovative therapies targeting disorders associated with the TGF-ß family of proteins. Recently, the company announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will represent...

Continue Reading
KULR Technology Unveils Major Licensing Breakthrough with Japan

Updated Category News Views 133

KULR Technology Group, Inc. (NYSE American: KULR) unveiled a major licensing agreement back in 2024 that had traders buzzing. This $2.35 million deal centered around their vibration reduction technology, known as KULR Xero Vibe (KXV). At first glance, it seemed like a solid step for the company into new markets, but let’s peel back the layers and see what's really...

Continue Reading
Mainz Biomed Achieves Significant Milestones and Results

Updated Category News Views 204

Mainz Biomed Reports Financial Results and Strategic Progress Lab network revenue up by 33% year-over-year. Operating loss down by 30% and net loss by 18%. Partnerships driving innovation and growth forward. Highlighting 2025 accomplishments and future goals. Mainz Biomed N.V. (NASDAQ: MYNZ), a pioneering molecular genetics diagnostic firm, has reported its financial...

Continue Reading
PioCreat Launches Innovative Mini Dental 3D Printer During Expo

Updated Category News Views 247

PioCreat Launches Innovative Mini Dental 3D Printer at Moscow Event PioCreat, a well-respected name in the 3D printing sector, made a significant impression at the dental industry's notable event, the 2025 Moscow Dental Expo. This gathering, renowned for showcasing advancements in digital dentistry, took place at Crocus-Expo IEC, attracting a wide array of international...

Continue Reading